



Department of  
**Health**

An Roinn Sláinte

Máinnstríe O Poustie

[www.health-ni.gov.uk](http://www.health-ni.gov.uk)

**For Action:** Assistant Director Integrated Care, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group & BSO  
Heads of Pharmacy and Medicines Management of HSC Trusts  
Regulation Quality Improvement Authority

From: Chief Pharmaceutical Officer  
Professor Cathy Harrison  
Castle Buildings  
Upper Newtownards Road  
Belfast BT4 3SQ

Telephone: 028 90 523219  
Facsimile: 028 90 522335

E-Mail: [cathy.harrison@health-ni.gov.uk](mailto:cathy.harrison@health-ni.gov.uk)

Our Ref: PHC/19/2024  
Date: 3<sup>rd</sup> June 2024

# MEDICINES NOTIFICATION

## CLASS 4 MEDICINES DEFECT INFORMATION

### Caution in Use Pharmacy / Wholesaler Level

Dear Healthcare Professional,

**Manx Healthcare Ltd.**

**Betamethasone Valerate 0.1% Ointment**

**PL 14251/0010**

---

**SNOMED Code: 41207211000001102**

Batch No	Expiry Date	Pack Size	First Distributed
G0039	Feb-2027	30g	April 2024

Active Pharmaceutical Ingredient: Betamethasone valerate

### Brief description of the problem

Manx Healthcare Ltd. has informed MHRA that they have identified a problem with the product packaging of the batch indicated in the table. The tamper-evident seal on the outer carton may be missing or deformed on some packs. This is due to an intermittent equipment fault during secondary packaging.

### **Advice for healthcare professionals**

The quality of the ointment is not impacted by the defect. Any packs from this batch of product with missing or deformed seals may be dispensed. Healthcare professionals dispensing this medication may wish to advise patients that the seal on the outer carton may be broken but this will not affect product quality.

### **Advice for patients**

The quality of the ointment is not impacted by the manufacturing issue as it only affects the outer carton. The tube of ointment that the patient receives will be sealed. Patients should continue to take medicines from this batch as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the [MHRA Yellow Card scheme](#).

### **Further Information**

For medical information enquiries please contact [medinfo@manxhealthcare.com](mailto:medinfo@manxhealthcare.com), or telephone: +44 (0)1926 482511.

For stock control enquiries please contact [customerservice@manxhealthcare.com](mailto:customerservice@manxhealthcare.com), or telephone: +44 (0)1926 482511.

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. RQIA should bring this information to the attention of private hospitals/clinics registered with them and any other relevant care facilities.

The Business Services Organisation is asked to bring this information to the attention of Community Pharmacists and General Medical Practitioners directly.

Yours sincerely

A handwritten signature in black ink, appearing to read "Cathy Harrison". The signature is fluid and cursive, with a long horizontal stroke at the end.

**Professor Cathy Harrison**  
**Chief Pharmaceutical Officer**